Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01294670 · ClinicalTrials.gov registry record · Phase 1

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

A Phase 1 study of Solid Tumors and Relapsed/Refractory Sarcomas, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target
11
Study locations

NCT01294670 is a Phase 1 study of Solid Tumors and Relapsed/Refractory Sarcomas that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 27 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (90% lower). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01294670, a Phase 1 study of Solid Tumors and Relapsed/Refractory Sarcomas, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to find out how safe and effective treatment with a new combination of drugs, vorinostat and etoposide, is in treating cancer. The medication etoposide is a standard medication used in the treatment of cancer in children. Vorinostat is an experimental drug which targets a protein(s) that control the way cancer cells grow and divide. Vorinostat is approved by the FDA in adults with certain cancers but not approved yet in children. There are two parts to this study. In the first part of this study, the phase I portion, a safe dose of the combination, vorinostat and etoposide. The goal of second part of this study, the phase II portion, is to see how effective the combination of vorinostat and etoposide is in treating cancer.

Conditions Studied

Solid Tumors Relapsed/Refractory Sarcomas

Interventions

  • DRUG Vorinostat and Etoposide

Study Locations (11)

Florida

  • Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando - Orlando
  • All Children's Hospital - St. Petersburg

Arizona

  • Phoenix Children'S Hospital - Phoenix

Colorado

  • Children's Hospital Colorado - Aurora

Maryland

  • John Hopkins Medical Center - Baltimore

Massachusetts

  • Dana Farber Cancer Institute - Boston

Missouri

  • Children's Mercy Hospital & Clinics - Kansas City

New York

  • Memorial Sloan Kettering Cancer Center - New York

Pennsylvania

  • Pennsylvania State University College of Medicine - Hershey

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2011-02-09
Est. Completion 2020-12-08
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01294670

The ClinicalTrials.gov registry entry for NCT01294670 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (90% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Vorinostat and Etoposide is the first listed.

NCT01294670 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Florida, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT01294670 about?

NCT01294670 is a clinical study titled "Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors". The purpose of this study is to find out how safe and effective treatment with a new combination of drugs, vorinostat and etoposide, is in treating cancer. The medication etoposide is a standard medication used in the treatment of cancer in children. Vorinostat is an experimental drug which targets ...

What is the current status of trial NCT01294670?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2011-02-09. Estimated completion is 2020-12-08.

What conditions does trial NCT01294670 study?

This clinical trial studies the following conditions: Solid Tumors, Relapsed/Refractory Sarcomas.

What interventions are being tested in trial NCT01294670?

The interventions under investigation include: Vorinostat and Etoposide (DRUG).

Who is sponsoring clinical trial NCT01294670?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01294670 being conducted?

This trial has 11 study locations across Arizona, Colorado, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Relapsed/Refractory Sarcomas

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.